AlivaMab Biologic (AMB) sets its partners’ antibody discovery programs on the fastest and most de-risked path through discovery and development. Trusted by top-tier pharmaceutical and biotechnology companies, AMB delivers drug-quality, fully human antibodies on exceptional timelines. AMB rapidly and efficiently delivers truly molecularly diverse panels of antibodies, characterized for function, kinetics, and developability, and offers downstream capabilities in antibody engineering for advanced modalities, including multispecifics and CARs. The AMB team’s experience in antibody drug discovery and development comes from many of the world’s top 15 pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech, and translates across more than 500 discovery programs and 35 clinical candidates. This experience, combined with the use of trusted, proven technologies, including Ablexis’ AlivaMab® Mouse platforms, ensures the highest probability of success.
To empower our partners with the most efficient and de-risked path through therapeutic antibody discovery and development.
A healthier world through partnerships that bring better medicines to patients faster.
10350 Barnes Canyon Road, Suite 100
San Diego, CA 92121
Get in Touch